APA (7th ed.) Citation

Berton-Rigaud, D., Pautier, P., Lorusso, D., Gennigens, C., Gladieff, L., Kryzhanivska, A., . . . Van Gorp, T. (2023). 755P Retifanlimab in patients with recurrent microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) endometrial cancer: Final results from the POD1UM-101 study (Cohort H). Annals of Oncology, 34, S517. https://doi.org/10.1016/j.annonc.2023.09.1934

Chicago Style (17th ed.) Citation

Berton-Rigaud, D., et al. "755P Retifanlimab in Patients with Recurrent Microsatellite Instability-high (MSI-H) or Deficient Mismatch Repair (dMMR) Endometrial Cancer: Final Results from the POD1UM-101 Study (Cohort H)." Annals of Oncology 34 (2023): S517. https://doi.org/10.1016/j.annonc.2023.09.1934.

MLA (9th ed.) Citation

Berton-Rigaud, D., et al. "755P Retifanlimab in Patients with Recurrent Microsatellite Instability-high (MSI-H) or Deficient Mismatch Repair (dMMR) Endometrial Cancer: Final Results from the POD1UM-101 Study (Cohort H)." Annals of Oncology, vol. 34, 2023, p. S517, https://doi.org/10.1016/j.annonc.2023.09.1934.